Talabostat · BXCL701

What is Talabostat?

Talabostat (BXCL701) is an orally active small molecule inhibitor of dipeptidyl peptidases, including fibroblast activation protein (FAP). By cleaving N-terminal Xaa-Pro or Xaa-Ala residues, it stimulates cytokine and chemokine production, T-cell immunity, and hematopoiesis. It is studied in pancreatic cancer, prostate cancer, neuroendocrine tumors, and small cell carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

BXCL701

Drug type

Small molecule

Targets

fibroblast activation protein (FAP), dipeptidyl peptidases

Mechanism

Inhibitor of fibroblast activation protein (FAP) and dipeptidyl peptidases

Pathways

cytokine production, chemokine production, T-cell immunity, hematopoiesis

Therapy area

Oncology

Developer

Point Therapeutics

In trials of

BTAI, IQV

FDA status

Investigational, not approved in the US. Most advanced trial: Phase 2

UNII

KZ1O2SH88Z

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Metastatic Pancreatic Ductal AdenocarcinomaCancer of PancreasCancer of the PancreasNeoplasms, PancreaticNeuroendocrine TumorsPancreas CancerPancreatic CancerProstate CancerSmall Cell Carcinoma

Other drugs acting on FAP

Sources

• NCI Thesaurus
• NCI Thesaurus
• ClinicalTrials.gov NCT03910660
• ClinicalTrials.gov NCT04123574
• ClinicalTrials.gov NCT05558982

Updated Oct 3, 2026.